News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–47
Matches
47
Sources here
11
Companies here
1
Search results Stored financial headlines

Active search

47 matching headlines

Ticker or company: LBRXMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

The Globe and Mail Analyst action Main company 🇺🇸 United States

Analysts Offer Insights on NA Companies: Exodus Movement, Inc. Class A (EXOD) and LB Pharmaceuticals, Inc. (LBRX)

Two analysts have issued bullish sentiments on Exodus Movement, Inc. Class A (EXOD) and LB Pharmaceuticals, Inc. (LBRX). Michael Grondahl of Northland Securities maintained a Buy rating on Exodus Movement with a $10.00 price target, while Yasmeen Rahimi of Piper Sandler maintained a Buy …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

LB Pharmaceuticals Inc (LBRX) stock price, news, quote and history

This article provides a comprehensive overview of LB Pharmaceuticals Inc (LBRX), a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric diseases. It includes information on the company's stock performance, key financial metrics, analyst ratings, and a profile of their lead product, LB-102, which …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

LB Pharmaceuticals accelerates schizophrenia trial timeline

LB Pharmaceuticals announced that it anticipates reporting results from its Phase 3 NOVA-2 clinical trial for schizophrenia in the first half of 2027, sooner than its initial projection of the second half of 2027, owing to faster-than-expected patient enrollment. The company also confirmed it …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

LB Pharmaceuticals announced accelerated timing for topline results from its pivotal Phase 3 NOVA-2 clinical trial of LB-102 for schizophrenia, now expected in the first half of 2027 due to rapid enrollment. This will be followed by a pre-NDA meeting with the FDA in …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
nasdaq.com Deals and strategy Main company 🇺🇸 United States

Biotech Stocks At 52-Week Highs - ADVB Surges +73%, BLFS Rises After Acquisition, FBRX, SLN, LBRX

(RTTNews) - The following biotech stocks reached a 52-week high on July 22, 2026, driven by key catalysts including prospective clinical trial results and announced acquisitions. Advanced Biomed Inc. (ADVB) Advanced Biomed is a biotechnology company advancing biomedical technologies for cancer detection and precision …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

LB Pharmaceuticals Expects Results From 460-Patient Trial in 1H 2027

LB Pharmaceuticals announced accelerated timing for topline results from its pivotal Phase 3 NOVA-2 trial of LB-102 for schizophrenia, now expected in the first half of 2027, sooner than the previous guidance of the second half of 2027. This acceleration is due to faster-than-expected …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Jennison Associates LLC Sells 283,636 Shares of LB Pharmaceuticals Inc $LBRX

Jennison Associates LLC reduced its stake in LB Pharmaceuticals Inc (NASDAQ:LBRX) by 34.5% during the first quarter, selling 283,636 shares and bringing its total ownership to 538,216 shares valued at $13.27 million. Other institutional investors like Jefferies Financial Group Inc. and Balyasny Asset Management …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
Bitget Analyst action Main company 🇺🇸 United States

LB PHARMACEUTICALS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $46

BMO has initiated coverage on LB Pharmaceuticals Inc. (LBRX.O) with an "Outperform" rating, setting a target price of $46. This reflects a positive outlook on the company's stock by the analyst firm. The article does not provide specific reasons for the rating but states …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

LBRX Initiated Coverage by BMO Capital -- Rated Outperform at $4

BMO Capital has initiated coverage on LB Pharmaceuticals (LBRX) with an "Outperform" rating and a price target of $46.00. This positive outlook is supported by other analysts, despite LBRX having a low GF Score™ of 12/100, which indicates weaknesses in profitability. However, the company …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
Investing.com South Africa Analyst action Main company 🇺🇸 United States

BMO initiates LB Pharmaceuticals stock at Outperform on drug data By Investing.com

BMO Capital has initiated coverage on LB Pharmaceuticals Inc (NASDAQ:LBRX) with an Outperform rating and a $46.00 price target, citing promising Phase 2 data for its LB-102 antipsychotic therapy. The drug demonstrated fast action efficacy and a large effect size for schizophrenia treatment, increasing …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

Price to book forward of LB Pharmaceuticals Inc – NASDAQ:LBRX

The article focuses on the "Price to book forward" financial metric for LB Pharmaceuticals Inc (NASDAQ: LBRX). It presents a page from TradingView, specifically the financials section for the company, indicating the availability of this data alongside other financial information. The article does not …

LBRX main company
Sharemaestro market context Trend signal active 49 weeks +184.4% · Next-week setup positive 67.7% LBRX stored weekly price path from 12 Sep 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context